T-lymphocyte interferon-γ receptor binding in patients with myasthenia gravis

Archives of Neurology

Volumn 56, Issue 8, 1999, Pages 933-938

  Bongioanni, Paolo ^a   Ricciardi, Roberta ^a   Romano, Maria Rosaria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 2; INTERLEUKIN RECEPTOR; PYRIDOSTIGMINE; TUMOR NECROSIS FACTOR;

ADULT; AMBULATORY CARE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOSTIMULATION; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; PATIENT SELECTION; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; BIOLOGICAL MARKERS; CELL MOVEMENT; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PYRIDOSTIGMINE BROMIDE; RECEPTORS, INTERFERON; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

EID: 0032817719     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.8.933     Document Type: Article

References (26)

1. Newsom-Davis J. Autoimmunity in neuromuscular disease. Ann N Y Acad Sci. 1988;540:25-38.
2. Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;396:125-131.
3. Kao I, Drachman DB. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977;196:527-529.
4. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med. 1982;307:769-775.
5. Engel AG, Sahashi K, Lambert EH, Howard FM. In: Aguayo AJ, Karpati G, eds. Current Topics in Nerve and Muscle Research. Amsterdam, the Netherlands: Excerpta Medica; 1979:111-122.
6. Rouveix B, Blin O. Pharmacological basis of immunotherapy in autoimmune diseases. Clin Neuropharmacol. 1993;16:104-112.
7. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today. 1985;6:131-136.
8. Kott E, Hahn T, Huberman M, et al. Interferon system and natural killer cell activity in myasthenia gravis. QJM. 1990;76:951-960.
9. Confalonieri P, Antozzi C, Comelio F, et al. Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon gamma and tumor necrosis factor-α levels in patients' serum. J Neuroimmunol. 1993;48:33-36.
10. Link J. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol Scand Suppl. 1994;158:1-58.
11. Link J, Navikas V, Yu M, et al. Augmented interferon-γ, interleukin-4 and transforming growth factor-β mRNA expression in blood mononuclear cells in myasthenia gravis. J Neuroimmunol. 1994;51:185-192.
12. Link J, Söderström M, Ljungdahl A, et al. Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology. 1994;44:728-734.
13. Yi Q, Lefvert AK. Idiotype- and anti-idiotype-reactive T lymphocytes in myasthenia gravis: evidence for the involvement of different subpopulations of T helper lymphocytes. J Immunol. 1994;153:3353-3359.
14. Asthana D, Fujii Y, Huston GE, Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol. 1993;67:240-248.
15. Wang ZY, Link H, Ljungdahl A, et al. Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol. 1994;157:353-368.
16. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell. 1988;55:273-280.
17. 125I-interferon-γ to receptors on human cells. J Biol Chem. 1985;260:1191-1198.
18. 125I-labeled recombinant human γ-interferon to receptors on WISH cells. Proc Natl Acad Sci U S A. 1984;81:5160-5167.
19. Valente G, Ozmen L, Novelli F, et al. Distribution of interferon-γ receptor in human tissues. Eur J Immunol. 1992;22:2403-2412.
20. Faltynek CR, Princler GL. Modulation of interferon-α and interferon-γ receptor expression during T-lymphocyte activation and proliferation. J Interferon Res. 1986;6:639-653.
21. Osserman KE. Myasthenia Gravis. New York, NY: Grune & Stratton; 1958:79-86.
22. Besinger UA, Toyka KV, Hömberg M, et al. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983;33(suppl 10):1316-1321.
23. Bongioanni P, Lombardo F, Fioretti C, Meucci G. T-lymphocyte immuno-interferon receptors in patients with multiple sclerosis. J Neurol. 1996;243:605-610.
24. Gibbs VC, Williams SR, Gray PW, et al. The extracellular domain of the human interferon γ receptor interacts with a species-specific signal transducer. Mol Cell Biol. 1991;11:5860-5866.
25. McPherson GA. Kinetic, EBDA, LIGAND, Lowry: A Collection of Radioligand Binding Analysis Programs. Amsterdam, the Netherlands: Elsevier; 1985.
26. Nicola NA. Guidebook to Cytokines and Their Receptors. Oxford, England: Sambrook & Tooze Publication at Oxford University Press; 1994.